BDX stock is trading near $145 — we rate Becton Dickinson an accumulate-on-weakness Buy with a $189 average analyst price target, after the company beat Q2 2026 adjusted EPS, raised full-year guidance, and printed a 24.2% adjusted operating margin despite a 160-bps tariff drag. If Becton Dickinson just beat on EPS, raised full-year guidance, and trades at 13x earnings — why is BDX stock still down 20% over the past year? That contradiction is the whole reason the BDX stock price deserves a fresh look in May 2026. The setup is best for patient accumulators rather than momentum traders: Q2 2026 earnings ($4.71B revenue, $2.90 adjusted EPS) showed durable margin discipline, and BD's full-year EPS guidance lift to $12.52–$12.72 suggests Street estimates still under-rate the operating leverage left in the business.
Key BDX Stock Data
| Metric | Value |
| Current Price | ~$145.00 |
| 52-Week Range | $135.00 – $245.00 |
| Market Cap | ~$41.5B |
| P/E Ratio (TTM) | ~13x |
| 2026 Adjusted EPS Guidance | $12.52 – $12.72 |
| Analyst Consensus | Buy |
| Average Price Target | $189.00 |
| Dividend Yield | ~2.72% |
| TTM Dividend | $4.20 |
Table of Contents
- Key BDX Stock Data
- BDX Stock Key Takeaways
- What Is Becton Dickinson (BDX)?
- Recent BDX Stock Performance and Q2 2026 Earnings
- BDX Stock Valuation and the 13x P/E Debate
- Bullish and Bearish Analyst Opinions on Becton Dickinson
- BDX Analyst Targets and Price Forecast
- BDX Stock Dividend and Shareholder Returns
- BDX Stock FAQs
BDX Stock Key Takeaways
- Price and verdict. BDX stock trades near $145 with a Buy consensus and a $189 average price target — about 30% implied upside, but the setup is best for patient accumulators rather than momentum traders.
- Headline stat. Q2 2026 adjusted EPS of $2.90 beat the $2.80 consensus by 3.5%; revenue of $4.71B grew 2.6% FX-neutral, with biologic drug delivery, Advanced Patient Monitoring, PureWick, and Advanced Tissue Regeneration all posting double-digit growth.
- Bull case. A 13x P/E sits well below the medtech peer average; adjusted operating margin of 24.2% beat internal expectations; full-year EPS guidance raised to $12.52–$12.72 even with 160 bps of tariff headwinds.
- Bear case. Trailing 12-month total return is negative 20%, divestitures complicate the comparison set, and one-time unusual items reduced reported profit by $1.3 billion last year. Trust takes time to rebuild.
- What we'd watch. Tariff offsets in H2, the pace of the BD Biosciences separation, and whether Citigroup's downgrade attracts copycats from other large-cap medtech desks.
What Is Becton Dickinson (BDX)?
Becton, Dickinson and Company (NYSE: BDX) is a global medical-technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products to hospitals, physicians, life-science researchers, and pharmaceutical companies in more than 190 countries. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD operates through three reporting segments — BD Medical, BD Life Sciences, and BD Interventional — and counts more than 70,000 employees worldwide. Its product catalogue spans syringes, IV catheters, infusion pumps, drug-delivery systems, advanced patient monitoring, microbiology automation, and surgical instruments.
The BDX investment thesis rests on two pillars. First, BD is one of the few healthcare names that combines the recurring-revenue stability of consumables (single-use syringes, IV sets, blood-collection tubes) with the multiple-expansion potential of higher-growth interventional and biopharma-services businesses such as PureWick, Advanced Patient Monitoring, and biologic drug delivery. Second, BD has paid an uninterrupted dividend for more than half a century and currently sits in the Dividend Aristocrat tier, which gives the stock a quality-and-income profile that screens well for institutional portfolios when growth names hit air pockets. The current 2.72% yield is above its 10-year average. Comparable medtech peers including Abbott Laboratories and Edwards Lifesciences trade at richer multiples, which underpins the "value within healthcare" thesis that bulls keep returning to.
Recent BDX Stock Performance and Q2 2026 Earnings
BDX stock has lagged the broader medtech tape for most of the past year. The 12-month total return sits at roughly negative 20%, with the stock pressured by a mix of factors: tariff exposure on China-sourced inputs, near-term margin friction from the planned separation of BD Biosciences, and a sequence of news items including unusual non-cash items that reduced reported profit by $1.3 billion last year. Yet inside the noise, the underlying performance has steadied. Shares are trading near $145 versus a 52-week range that hit a high above $240 — a discount that bulls argue more than discounts the known overhangs.
The Q2 2026 print on May 7 was the turning point that made the stock interesting again. BD reported $4.71 billion in revenue (just $5 million shy of the $4.716 billion consensus) and adjusted EPS of $2.90 (versus $2.80 expected), a 3.5% beat. More than 90% of the portfolio delivered mid-single-digit growth and four product lines — biologic drug delivery, Advanced Patient Monitoring, PureWick, and Advanced Tissue Regeneration — printed double-digit growth. Adjusted operating margin expanded to 24.2%, ahead of internal expectations. Tariffs cost the company 160 bps of gross margin but were offset by 70 bps of productivity gains plus positive mix, leaving adjusted gross margin at 54.7% — down only 90 bps year over year. Management then raised the full-year adjusted EPS guidance range to $12.52–$12.72. That is the kind of guide-up that tends to attract long-only capital, particularly into a stock already trading at a 13x P/E.
BDX Stock Valuation and the 13x P/E Debate
The single number that defines the current BDX stock debate is its 13x trailing P/E. That figure is roughly half of where the broader medtech peer set trades, and it puts BD in territory typically reserved for businesses in structural decline — which BD demonstrably is not, given the Q2 2026 print. The table below frames the valuation gap.
| Metric | BDX | Medtech Peer Avg | Implied at Peer Multiple |
| P/E (TTM) | ~13x | ~22x | ~$245 |
| EV/EBITDA | ~11x | ~16x | ~$210 |
| Forward P/E (FY26) | ~11.5x | ~19x | ~$240 |
| Dividend Yield | 2.72% | ~1.0% | — |
At today's 13x P/E and the midpoint of guidance ($12.62 EPS), BDX is priced as if forward earnings will be revised lower — a stance that is increasingly hard to defend after a guide-up. Re-rating just to the medtech peer-average multiple would imply a stock price north of $200, and even a halfway re-rate puts BDX comfortably above $170. Bears counter that the unusual-items overhang ($1.3B impact last year) plus the BD Biosciences separation creates a wider-than-normal range of outcomes that justifies a discount. We agree the discount is warranted — but at half the peer multiple, it likely overshoots. For a deeper BDX stock price analysis, the sensitivity matters: every one-turn re-rate of P/E adds roughly $13 to the share price.
Bullish and Bearish Analyst Opinions on Becton Dickinson
The analyst community has begun to migrate toward the bullish view, but the spread between named desks remains material. Of the analysts covering BDX, seven carry Buy, nine carry Hold, and zero carry Sell — which produces a Buy consensus on a weighted basis. The named-firm view is more contested than the aggregate suggests.
| Camp | Firm | Rating | Price Target | Core Thesis |
| Bullish | Barclays | Overweight | $204 | Q2 EPS beat plus guidance raise warrants re-rate toward peer multiple |
| Bullish | Wall Street Consensus | Buy | $209.81 | 13x P/E too cheap for 24%+ operating margin profile |
| Neutral | Citigroup | Neutral (downgrade) | ~$170 | BD Biosciences separation creates execution overhang |
| Cautious | Piper Sandler | Neutral | $159 | Tariff drag plus FX limit near-term upside |
| Bearish | Sector Skeptic | Sell | $135 | Unusual items distort the picture; wait for clean comps |
The bullish argument concentrates on three points: a 13x P/E that screens as the cheapest large-cap medtech multiple in years, a Q2 2026 EPS beat plus guidance raise that suggests operating discipline is improving rather than deteriorating, and a 2.72% dividend yield that compensates investors for waiting through the re-rate. The bearish argument concentrates on near-term noise: $1.3B of unusual items distorted last year's profit comparison, the BD Biosciences separation introduces transitional friction, and tariffs continue to weigh on gross margin even after productivity offsets. Our read: the bullish case is mechanically stronger because the math of a forward-looking re-rate dominates near-term headline volatility — but only if BD delivers on guidance for two more consecutive quarters.
BDX Analyst Targets and Price Forecast
The analyst price-target distribution on BDX stock spans a wide range that reflects exactly the divergence above. Across the 14 to 17 analysts publishing, the average 12-month price target sits between $188 and $210; the high estimate reaches $225 and the low estimate is $157. From a $145 print, the average target implies roughly 30% upside; the high target implies 55% upside; the low estimate implies 8% upside — meaning even the bear case isn't calling for material downside from today's level. That asymmetric setup is unusual for a large-cap healthcare name and is consistent with the "accumulate on weakness" framing.
Our base-case BDX stock price forecast for the next 12 months sits at $185 — a partial re-rate to the peer-adjusted multiple, justified by Q2 beat momentum, the guidance lift, and the dividend cushion. The bull case at $210–$225 (matching Wall Street consensus and the high target) requires BD to hit the upper end of guidance and complete the BD Biosciences separation without delays. The bear case at $135–$140 requires another quarter of tariff drag plus a guidance cut — which Q2 explicitly argued against. Investors holding BDX through Q3 should focus on: (1) gross-margin progression, (2) any commentary on the BD Biosciences separation, and (3) free-cash-flow conversion for dividend coverage.
BDX Stock Dividend and Shareholder Returns
One of the most under-discussed parts of the BDX story is the dividend. Becton Dickinson has paid an uninterrupted dividend for more than 50 years, putting it in the Dividend Aristocrat club alongside a small set of large-cap healthcare and consumer-staples names. The TTM payout of $4.20 per share works out to a 2.72% yield at the current BDX stock price — comfortably above BD's own 10-year average yield and roughly 2.7x the medtech peer average. The three-year average dividend growth rate sits at 6.27%, which means investors who buy and hold through the current pullback are compounding income at a meaningful rate on top of any capital appreciation.
Compared with adjacent dividend-paying pharma and medtech names — including AbbVie stock price, Amgen stock price, and Abbott Laboratories stock price — BDX offers a less-loved entry point with a similar quality-and-income profile. The trade-off is that BDX's growth rate is structurally lower than biotech-heavy peers, but its earnings predictability is higher. For long-horizon income investors, that combination is exactly the kind of setup that rewards accumulation during drawdowns — provided position sizes are calibrated to a multi-quarter holding period.
It's also worth flagging the buyback contribution. BD has been repurchasing shares opportunistically through the drawdown, which mechanically supports EPS growth even when revenue compounds at a low-single-digit rate. Combined with the dividend, total shareholder return capacity sits in the high single digits before any multiple expansion — and double digits if the re-rate to peer multiples plays out over 18 to 24 months. That math is exactly what makes BDX a defensible holding in a balanced healthcare allocation.
BDX Stock FAQs
Is BDX a good stock to buy in 2026?
For income-focused or value-tilted investors, BDX stock at $145 looks like an accumulate-on-weakness Buy. The 13x P/E is roughly half the medtech peer average, the 2.72% dividend yield offers a tangible cushion, and the Q2 2026 beat plus guidance raise removes the worst near-term fundamental risk. Patience matters: this is a 12- to 18-month re-rating story, not a momentum trade.
What are the bullish and bearish analyst opinions on Becton Dickinson stock?
It depends on which desk you read. Barclays (Overweight, $204) and the broader Wall Street consensus ($209.81) lean bullish on the multiple-expansion thesis after the Q2 beat. Citigroup (Neutral, downgrade) and Piper Sandler ($159) lean cautious because the BD Biosciences separation and tariff drag complicate near-term visibility. The aggregate consensus is Buy, but the spread between bullish and bearish desks is one of the widest in large-cap medtech.
What was Becton Dickinson's Q2 2026 earnings result?
BD reported Q2 2026 revenue of $4.71 billion (against the $4.716B consensus) and adjusted EPS of $2.90 (versus $2.80 expected) — a 3.5% EPS beat. Adjusted operating margin came in at 24.2%, and the company raised full-year adjusted EPS guidance to $12.52–$12.72. Four product lines (biologic drug delivery, Advanced Patient Monitoring, PureWick, Advanced Tissue Regeneration) printed double-digit growth.
Why has BDX stock been down 20% over the past year?
The drawdown is more about sentiment than fundamentals. Tariffs hit gross margin by 160 bps, the BD Biosciences separation created execution-overhang concerns, and $1.3 billion of unusual non-cash items distorted reported profit comparisons. None of those items invalidates the underlying business — they just take time to work through the income statement. Q2 2026 results suggest the worst of the headline overhang is in the past.
Does Becton Dickinson pay a dividend?
Yes. BD has paid an uninterrupted dividend for more than 50 years, making it a Dividend Aristocrat. The TTM payout is $4.20 per share, which equates to a 2.72% yield at the current BDX stock price — roughly 2.7x the medtech peer average yield. The three-year dividend growth rate is 6.27%, and the payout is supported by consistent free-cash-flow generation.
Disclaimer
This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Past performance does not guarantee future results. Investors should conduct thorough due diligence and consult qualified financial advisors before making investment decisions.
MEXC is a global cryptocurrency exchange committed to “MEXCmize Your Opportunities.” Serving over 40 million users across 170+ countries, MEXC offers access to more than 3,000 digital assets across spot and derivatives markets. Known for its high liquidity and broad selection of trending tokens, the platform is designed to support both new traders and experienced investors. MEXC also continues to enhance trading efficiency through innovations such as zero trading fees, while prioritizing a secure, user-friendly, and accessible trading experience. Select MEXC as Your 0-fee Gateway To Infinite Opportunities.